| P2093 | author name string | David J Mooney | |
| | Alessandra B Ennett | |
| P2860 | cites work | Angiopoietin-2, a natural antagonist for Tie2 that disrupts in vivo angiogenesis | Q24313372 |
| | Origins of circulating endothelial cells and endothelial outgrowth from blood | Q24599869 |
| | Tumor angiogenesis: therapeutic implications | Q27860595 |
| | Isolation of putative progenitor endothelial cells for angiogenesis | Q28302884 |
| | Vascular-specific growth factors and blood vessel formation | Q29614780 |
| | Mechanisms of angiogenesis and arteriogenesis | Q29617257 |
| | Tissue engineering | Q29617288 |
| | Unhealthy effects of atmospheric temperature and pressure on the occurrence of myocardial infarction and coronary deaths. A 10-year survey: the Lille-World Health Organization MONICA project (Monitoring trends and determinants in cardiovascular dise | Q33420805 |
| | Effects of chronic systemic administration of basic fibroblast growth factor on collateral development in the canine heart | Q33490052 |
| | Seeding of intracoronary stents with endothelial cells: current status and future prospects | Q33568862 |
| | Hemangioblast development and regulation | Q33678416 |
| | Angiogenesis gene therapy: phase I assessment of direct intramyocardial administration of an adenovirus vector expressing VEGF121 cDNA to individuals with clinically significant severe coronary artery disease | Q33869745 |
| | Clinical trials in coronary angiogenesis: issues, problems, consensus: An expert panel summary | Q33917476 |
| | Neovascularization of ischemic myocardium by human bone-marrow-derived angioblasts prevents cardiomyocyte apoptosis, reduces remodeling and improves cardiac function | Q33941111 |
| | Endogenous angiogenesis inhibitors and their therapeutic implications | Q33943217 |
| | Results from late-breaking clinical trials sessions at ACCIS 2000 and ACC 2000. American College of Cardiology | Q33970661 |
| | Endothelial cells derived from human embryonic stem cells | Q34048189 |
| | Gene transfer for angiogenesis in coronary artery disease. | Q34132035 |
| | Molecular mechanisms of blood vessel growth | Q34134535 |
| | Stimulation of arteriogenesis; a new concept for the treatment of arterial occlusive disease | Q34134554 |
| | Shear stress selectively upregulates intercellular adhesion molecule-1 expression in cultured human vascular endothelial cells | Q34229735 |
| | Gene therapy for therapeutic angiogenesis in critically ischaemic lower limb - on the way to the clinic | Q34319721 |
| | Vasculogenesis | Q34387300 |
| | Arteriogenesis: mechanisms and modulation of collateral artery development | Q34450132 |
| | Blood vessel maturation: vascular development comes of age | Q34489077 |
| | Endothelial progenitor cells for vascular regeneration | Q34619706 |
| | In vivo formation of complex microvessels lined by human endothelial cells in an immunodeficient mouse | Q35199743 |
| | Fluid shear stress induces a biphasic response of human monocyte chemotactic protein 1 gene expression in vascular endothelium | Q35265510 |
| | Adeno-associated viral vector-mediated vascular endothelial growth factor gene transfer induces neovascular formation in ischemic heart | Q35576360 |
| | Basic fibroblast growth factor enhances the coupling of intimal hyperplasia and proliferation of vasa vasorum in injured rat arteries | Q35597553 |
| | Vascular endothelial growth factor (VEGF)-mediated angiogenesis is associated with enhanced endothelial cell survival and induction of Bcl-2 expression | Q35745301 |
| | Vascular morphogenesis and differentiation after adoptive transfer of human endothelial cells to immunodeficient mice | Q35748093 |
| | Perivascular and intravenous administration of basic fibroblast growth factor: vascular and solid organ deposition | Q36111145 |
| | Signal transduction in the control of cell growth and development | Q36471850 |
| | Therapeutic angiogenesis with recombinant fibroblast growth factor-2 for intermittent claudication (the TRAFFIC study): a randomised trial | Q38522489 |
| | Pharmacological treatment of coronary artery disease with recombinant fibroblast growth factor-2: double-blind, randomized, controlled clinical trial | Q38523342 |
| | Open pore biodegradable matrices formed with gas foaming | Q38549421 |
| | Induction of neoangiogenesis in ischemic myocardium by human growth factors: first clinical results of a new treatment of coronary heart disease | Q39462155 |
| | Promotion of collateral growth by granulocyte-macrophage colony-stimulating factor in patients with coronary artery disease: a randomized, double-blind, placebo-controlled study | Q40594411 |
| | Intracoronary administration of recombinant human vascular endothelial growth factor to patients with coronary artery disease | Q40678937 |
| | DNA delivery from polymer matrices for tissue engineering | Q40945294 |
| | In vivo angiogenesis induced by recombinant adenovirus vectors coding either for secreted or nonsecreted forms of acidic fibroblast growth factor | Q41275923 |
| | Gene therapy for collateral vessel development. | Q41671835 |
| | Evaluation of the effects of intramyocardial injection of DNA expressing vascular endothelial growth factor (VEGF) in a myocardial infarction model in the rat--angiogenesis and angioma formation | Q41729529 |
| | VEGF contributes to postnatal neovascularization by mobilizing bone marrow-derived endothelial progenitor cells | Q42677798 |
| | Stabilization of proteins encapsulated in injectable poly (lactide- co-glycolide) | Q42806631 |
| | Transendocardial delivery of autologous bone marrow enhances collateral perfusion and regional function in pigs with chronic experimental myocardial ischemia | Q43602426 |
| | Seeding of intravascular stents with genetically engineered endothelial cells | Q44005674 |
| | Impact of different platelet glycoprotein IIb/IIIa receptor inhibitors among diabetic patients undergoing percutaneous coronary intervention: : Do Tirofiban and ReoPro Give Similar Efficacy Outcomes Trial (TARGET) 1-year follow-up | Q44023046 |
| | Six-month assessment of a phase I trial of angiogenic gene therapy for the treatment of coronary artery disease using direct intramyocardial administration of an adenovirus vector expressing the VEGF121 cDNA. | Q45862896 |
| | Arterial gene therapy for therapeutic angiogenesis in patients with peripheral artery disease | Q45866523 |
| | Direct intramuscular gene transfer of naked DNA encoding vascular endothelial growth factor augments collateral development and tissue perfusion | Q45880288 |
| | Gene therapy for myocardial angiogenesis: initial clinical results with direct myocardial injection of phVEGF165 as sole therapy for myocardial ischemia | Q45890406 |
| | Serum cholesterol-lowering activity of granulocyte-macrophage colony-stimulating factor. | Q45996679 |
| | Therapeutic angiogenesis with basic fibroblast growth factor: technique and early results | Q47910562 |
| | Drug-releasing scaffolds fabricated from drug-loaded microspheres. | Q53881680 |
| | Intracoronary basic fibroblast growth factor (FGF-2) in patients with severe ischemic heart disease: results of a phase I open-label dose escalation study. | Q53900090 |
| | Intrapericardial basic fibroblast growth factor induces myocardial angiogenesis in a rabbit model of chronic ischemia | Q58976540 |
| P433 | issue | 8 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | neovascularization | Q1281049 |
| | tissue engineering | Q1540285 |
| P304 | page(s) | 805-818 | |
| P577 | publication date | 2002-12-01 | |
| P1433 | published in | Expert Opinion on Biological Therapy | Q5421201 |
| P1476 | title | Tissue engineering strategies for in vivo neovascularisation | |
| P478 | volume | 2 | |